key: cord-0992544-3dd7aov4
authors: Letizia, Andrew G; Smith, Darci R; Ge, Yongchao; Ramos, Irene; Sealfon, Rachel S G; Goforth, Carl; Gonzalez-Reiche, Ana S; Vangeti, Sindhu; Weir, Dawn L; Alshammary, Hala; Chen, Hua Wei; George, Mary-Catherine; Soares-Schanoski, Alessandra; Lizewski, Rhonda A; Lizewski, Stephen E; Marayag, Jan; Miller, Clare M; Nunez, Edgar; Porter, Chad K; Ana, Ernesto Santa; Schilling, Megan; Sugiharto, Victor A; Sun, Peifang; Termini, Michael; van de Guchte, Adriana; Troyanskaya, Olga G; van Bakel, Harm; Sealfon, Stuart C
title: Viable virus shedding during SARS-CoV-2 reinfection
date: 2021-05-05
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(21)00219-8
sha: 3981a11936b80761da8ea013ff0751b42ac3a3bb
doc_id: 992544
cord_uid: 3dd7aov4

nan

Vero E6/TMPRSS2 cells to quantify the level of detectable infectious virus.

Viable virus was detected in only four (25%) of 16 participants, and only once in each, with titres ranging from 1·7 to 5·5 log 10 plaque-forming units per mL. Serology and PCR cycle threshold (Ct) values using the US Food and Drug Administrationauthorised Thermo Fisher TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Waltham, MA, USA) were compared in those with viable virus detected (shedders) and those without viable virus detected (nonshedders; table; appendix p 2). At the time of positive viral culture, samples from shedders had lower Ct values. Although all participants had detectable SARS-CoV-2 spike IgG at study enrolment, none of the four shedders and only four (33%) of the 12 non-shedders had detectable serum neutralisation activity (limit of detection was 50% inhibitory dilution of 20) in serum at the time of enrolment into the study (methods as described 2 ). Only one (25%) of the four who shed virus was symptomatic when viable virus was detected.

All reinfections occurred before December, 2020, when the B.1.1.7 variant was first reported in the USA. Full-length viral genome was recovered from seven (44%) of 16 participants studied by viral transport medium culturing, including all four culture-positive individuals (methods previously described 5 ). Although the strains isolated all had the Asp614Gly spike protein mutation and two of the isolates had the Leu18Phe spike protein mutation, they did not have mutations associated with the B.1.1.7, P.1, B.1.351, or other variants of concern as currently defined by the US Centers for Disease Control and Prevention (appendix p 3).

Limitations of our study are the use of virus culture as a proxy for capacity for transmission without direct study of transmission, the small sample size, the absence of specimens available for culturing from all reinfected participants, and the inability to compare potential for transmissibility between those who are infected for the first time and those who are reinfected.

Overall, our findings suggest that about a quarter of young healthy individuals with subsequent SARS-CoV-2 reinfection shed viable virus. Some of these individuals were asymptomatic and could unknowingly transmit SARS-CoV-2 to others. 

The reinfection risk in individuals previously infected with SARS-CoV-2 is about a fifth of those never infected. 1,2 Whether reinfected individuals shed viable virus has been identified as an important question relevant to pandemic control. 3 In a prospective cohort study in The Lancet Respiratory Medicine, 2 we identified 19 cases of reinfection in people who at study entry were seropositive for both SARS-CoV-2 receptor binding domain and fulllength spike protein, tested negative on three nasal swab PCR tests over a 2-week quarantine period, and subsequently developed a positive PCR test at least 2 weeks after leaving quarantine. 2 We have now investigated whether these SARS-CoV-2-reinfected individuals shed viable virus. Viral transport media was available from the first and some subsequent PCR-positive tests from 16 (84%) of 19 reinfected participants. Samples were cultured for SARS-CoV-2 in Vero E6 cells expressing TMPRSS2 4 in T25 cm² flasks and monitored for cytopathic effect for 4 days followed by a second passage onto fresh cells to allow additional time for virus amplification. Samples were simultaneously titred by plaque assay in Data are mean (SD) and n (%). Ranges are 95% CIs. When a participant has multiple PCR-positive samples from more than one visit day, only the data from the visit day with the lowest mean Ct values of the three viral genes were included in the data summary. Ct=PCR cycle threshold. ID 50 =50% inhibitory dilution. *Difference in mean for the continuous variables and difference in percentage for binary variables. 

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study

Coronavirus reinfections: three questions scientists are asking

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

SARS-CoV-2 transmission among marine recruits during quarantine